CSTL (Castle Biosciences Inc) רווחיות לפי רווח גולמי

סמל תאגידי ולוגו של Castle Biosciences Corp (CSTL)

Gross margin after deducting cost of goods sold reflects the dynamics of Castle Biosciences (CSTL), which is developing oncology diagnostics through clinic partnerships and the acquisition of AI services. An increasing number of dermatologists and insurance payouts are expanding the molecular testing market. The current metric is 74.10, however, geopolitical conflicts and reagent supply chain disruptions create serious risks for conducting global research.

רווחיות גולמית Castle Biosciences, Inc. (CSTL): לתקופה 04.07.2022 - 19.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת Castle Biosciences (CSTL)

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית:CSTL Castle Biosciences Corp
סחורת הדגל של Castle Bio

The high profitability of Castle Biosciences (CSTL) innovative tests creates powerful operating leverage, allowing the company to scale net income as unit costs decrease. By analyzing gross margin, an investor assesses the portion of revenue remaining after deducting direct production costs, which determines the fundamental efficiency of the business model and serves as the basis for calculating the company's fair value.